Holen Sie sich die Stockscreener-App
3.89
1.02%
-0.04
Schlusskurs vom Vortag:
$3.93
Offen:
$3.93
24-Stunden-Volumen:
24,409
Relative Volume:
0.35
Marktkapitalisierung:
$2.18B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-11.39%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$3.80
$4.1517
1-Wochen-Bereich:
$3.80
$4.728
52-Wochen-Spanne:
$3.23
$6.25
Sl Science Holding Ltd Stock (SLBT) Company Profile
Firmenname
Sl Science Holding Ltd
Sektor
Branche
Telefon
-
Adresse
-
Compare SLBT vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLBT
Sl Science Holding Ltd
|
3.89 | 2.20B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
481.27 | 121.95B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
671.52 | 70.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
870.41 | 52.94B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
181.10 | 38.35B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
276.23 | 36.40B | 4.29B | 577.22M | 641.34M | 4.2086 |
Sl Science Holding Ltd Aktie (SLBT) Neueste Nachrichten
Lok Sang Leung Net Worth (2026) - GuruFocus
SL Science presents glioblastoma treatment data at WCP 2026 - Investing.com UK
SL Science presents glioblastoma treatment data at WCP 2026 By Investing.com - Investing.com South Africa
Trevi Therapeutics Shares Surge 13% as Biopharma Investors Cheer Cough Drug Data at London Conference - International Business Times Australia
SL Science Holding Limited Exhibits Breakthrough Gamma Delta T Cell Therapy for Glioblastoma at 2026 World Congress of Basic and Clinical Pharmacology - marketscreener.com
SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology - The Manila Times
SL Science Showcases Preclinical Gamma Delta T Cell Study Demonstrating Glioblastoma Elimination at WCP 2026 - Quiver Quantitative
Preclinical γδ T cells eradicated a brain tumor by day 26 at highest dose - Stock Titan
4DMedical Shares Plunge 15.57% to $3.20 as Volatile ASX Healthcare Stock's Wild Ride Continues This Week - International Business Times Australia
Ericsson, Q32 Bio and other big stocks moving lower in Tuesday’s pre-market session - MSN
Ericsson, Q32 Bio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Sahm
SL Science seeks US orphan drug designation for γδ T-cell therapy - BioWorld News
Net current asset value per share of SL Science Holding Limited – BOATS:SLBT - TradingView
Number of employees of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Gross margin % of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Price to book ratio of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Net margin % of SL Science Holding Limited – NASDAQ:SLBT - TradingView
SL Science Holding Limited (SLBT-Q) Stock Price and News - The Globe and Mail
Enterprise value to revenue forward of SL Science Holding Limited – BOATS:SLBT - TradingView
Net debt of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Cash flow from investing activities of SL Science Holding Limited – BOATS:SLBT - TradingView
Price to earnings forward of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Enterprise value to EBIT forward of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Enterprise value to EBITDA forward of SL Science Holding Limited – NASDAQ:SLBT - TradingView
EBITDA margin % of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Debt to assets ratio of SL Science Holding Limited – BOATS:SLBT - TradingView
EBITDA per share of SL Science Holding Limited – BOATS:SLBT - TradingView
Debt to equity ratio of SL Science Holding Limited – BOATS:SLBT - TradingView
Enterprise value to EBITDA ratio of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Enterprise value to EBITDA forward of SL Science Holding Limited – BOATS:SLBT - TradingView
EBITDA margin % of SL Science Holding Limited – BOATS:SLBT - TradingView
Enterprise value to EBIT forward of SL Science Holding Limited – BOATS:SLBT - TradingView
Price to earnings forward of SL Science Holding Limited – BOATS:SLBT - TradingView
Price to sales forward of SL Science Holding Limited – BOATS:SLBT - TradingView
Price to book forward of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Enterprise value of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Return on equity % of SL Science Holding Limited – BOATS:SLBT - TradingView
Tangible book value per share of SL Science Holding Limited – BOATS:SLBT - TradingView
EBIT per share of SL Science Holding Limited – NASDAQ:SLBT - TradingView
EBIT per share of SL Science Holding Limited – BOATS:SLBT - TradingView
Cash flow from operating activities of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Cash flow from financing activities of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Asset turnover of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Free cash flow of SL Science Holding Limited – BOATS:SLBT - TradingView
Asset turnover of SL Science Holding Limited – BOATS:SLBT - TradingView
Cash per share of SL Science Holding Limited – BOATS:SLBT - TradingView
Total equity of SL Science Holding Limited – BOATS:SLBT - TradingView
EBITDA of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Total liabilities & shareholders' equities of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Total debt of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Long term debt to total equity ratio of SL Science Holding Limited – BOATS:SLBT - TradingView
Finanzdaten der Sl Science Holding Ltd-Aktie (SLBT)
Es liegen keine Finanzdaten für Sl Science Holding Ltd (SLBT) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):